



## Napsin A (Clone MRQ-60, Mouse)

- **New clone MRQ-60 (high dilution)**
- **Marker for lung adenocarcinomas** (more sensitive and more specific than TTF-1)
- **Subclassification of ovarian carcinomas**  
(clear cell histologic type: *Am J Clin Pathol* 2014; 142: 735 and 830)

### For discriminating:

- Primary lung adenocarcinoma vs. metastatic disease
- Adenocarcinoma vs. squamous cell carcinoma of the lung
- Lung adenocarcinoma (Napsin A+) vs. mesothelioma (Napsin A-)
- Origin lung (TTF-1+/- Napsin A+) vs. thyroid (TTF-1+ Napsin A-)

Lung carcinoma subtypes	TTF-1	Napsin A	Sox-2	p63	p40 (ΔNp63)	CK5	CK14
Lung adenocarcinoma (well differentiated)	+	+	-	-/+	-	-	-
Lung adenocarcinoma (poorly differentiated)	-/+	+	-	-/+	-	-	-
Squamous cell carcinoma	-	-	+	+	+	+	+

Tumour origin	GCDFP-15	Mamma-globin	CDX2	PSA	TTF-1	Napsin A polyclonal	Napsin A MRQ-60
Breast cancer	+	+	-	-	-	-	-
Lung adenocarcinoma	-	-	-	-	+	+	+
Colon cancer	-	-	+	-	-	-/+	-
Prostate cancer	-	-	-	+	-	-	-

The monoclonal napsin A antibody MRQ-60 (mouse) is characterised by **higher specificity/dilution** compared with polyclonal napsin A antibodies. **Napsin A** belongs to the group of pepsin-like aspartyl proteases (its name is derived as follows: *Novel aspartic proteinase of the pepsin family*). Napsin A is expressed in the normal **lung** parenchyma in type II pneumocytes and in the proximal and distal convoluted tubules of the **kidney**\*. The enzyme is present in the lung in the cytoplasm (lysosomes) of type II pneumocytes, Clara cells and alveolar macrophages (probably secondary to phagocytosis) and to a lesser degree in pancreatic acini and ducts. **Napsin A is a more sensitive and more specific marker for lung adenocarcinomas than TTF-1. More than 85% of primary lung adenocarcinomas are positive for napsin A.** Squamous cell carcinomas and small cell carcinomas of the lung are characteristically negative for napsin A. Adenocarcinomas of the breast and pancreas, as well as of the biliary tract and colon only rarely stain with napsin A. Pulmonary adenocarcinomas with *enteric differentiation* (PAED) are a special entity in that the vast majority of these cases are negative for napsin A.

\***Renal cell carcinomas** (3-4% of all cancers) are ~57% napsin A-positive (papillary 75-82% napsin A-positive; clear cell 10-43% positive; chromophobic 3% positive). Pax-8 helps to discriminate between tumour origin lung (napsin A+ Pax-8-) versus kidney (napsin A+/- Pax-8+).

## Ordering Information

Antibody	Clone	Species	Dilution	Concentrate			Ready to use/RTU		
				0.1 ml	0.5 ml	1.0 ml	1 ml	7 ml	6 ml
<b>CDX2</b>	EPR2764Y	Rabbit	100-500	235R-14	235R-15	235R-16	235R-17	235R-18	-
<b>CK5</b>	EP1601Y	Rabbit	50-200	305R-14	305R-15	305R-16	305R-17	305R-18	-
<b>CK5/6</b>	D5/16B4	Mouse	50-200	356M-14	356M-15	356M-16	356M-17	356M-18	-
<b>CK14</b>	LL002	Mouse	100-500	314M-14	314M-15	314M-16	314M-17	314M-18	-
<b>CK14</b>	SP53	Rabbit	100-500	314R-14	314R-15	314R-16	314R-17	314R-18	-
<b>GATA3</b>	L50-823	Mouse	100-500	390M-14	390M-15	390M-16	390M-17	390M-18	-
<b>GCDFP-15</b>	23A3	Mouse	50-200	257M-14	257M-15	257M-16	257M-17	257M-18	-
<b>GCDFP-15</b>	EP1582Y	Rabbit	25-100	257R-14	257R-15	257R-16	257R-17	257R-18	-
<b>Mammaglobin</b>	31A5	Rabbit	100-500	280R-14	280R-15	280R-16	280R-17	280R-18	-
<b>Napsin A</b>	MRQ-60	Mouse	100-500	352M-94	352M-95	352M-96	352M-97	352M-98	-
<b>Napsin A</b>	EP205	Rabbit	100-500	352R-14	352R-15	352R-16	352R-17	352R-18	-
<b>p40 (ΔNp63)</b>	polyclonal	Rabbit	50-200	-	RP163-05	-	-	-	PDR055
<b>p53</b>	DO-7	Mouse	100-500	453M-94	453M-95	453M-96	453M-97	453M-98	-
<b>p63</b>	4A4	Mouse	100	-	-	Z2003L	-	-	413751F
<b>Pax8</b>	polyclonal	Rabbit	25-100	363A-14	363A-15	363A-16	363A-17	363A-18	-
<b>Pax8</b>	MRQ-50	Mouse	50-200	363M-14	363M-15	363M-16	363M-17	363M-18	-
<b>PSA</b>	ER-PR8	Mouse	50-200	324M-14	324M-15	324M-16	324M-17	324M-18	-
<b>Sox2*</b>	SP76	Rabbit	50-200	371R-14	371R-15	371R-16	371R-17	371R-18	-
<b>TTF-1</b>	EP229	Rabbit	50-200	343R-14	343R-15	343R-16	343R-17	343R-18	-
<b>WT1</b>	6F-H2	Mouse	100-500	348M-94	348M-95	348M-96	348M-97	348M-98	-

\* Stem cell and pluripotency marker, \*\* 15 ml RTU (343M-99) and 25 ml (343M-90) are also available

### Napsin A references

- Whithaus K, *et al.* Evaluation of napsin A, cytokeratin 5/6, p63, and thyroid transcription factor 1 in adenocarcinoma versus squamous cell carcinoma of the lung. *Arch Pathol Lab Med* 2012; 136: 155-162.
- Turner BM, *et al.* Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray. *Arch Pathol Lab Med* 2012; 136: 163-171.
- Mukhopadhyay S, Katzenstein AL. Comparison of monoclonal Napsin A, polyclonal Napsin A, and TTF-1 for determining lung origin in metastatic adenocarcinomas. *Am J Clin Pathol* 2012; 138: 703-711.
- Ordóñez NG. Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: a review and update. *Hum Pathol* 2013; 44: 1-19.
- Siddiqui MT. TTF-1 and Napsin A double staining in diagnosing lung adenocarcinoma. *J Cytol Histol* 2012; 3: 596-602.
- Liu L, *et al.* Thyroid transcription factor 1 and napsin A double staining in lung adenocarcinoma in pleural fluid. *Acta Cytol* 2012; 56: 425-430.
- Ordóñez NG. A word of caution regarding napsin A expression in squamous cell carcinomas of the lung. *Am J Surg Pathol* 2012; 36: 396-401.
- Ye J, *et al.* Diagnostic utility of PAX8, TTF-1 and napsin A for discriminating metastatic carcinoma from primary adenocarcinoma of the lung. *Biotech Histochem* 2012; 87: 30-34.
- Kim JH, *et al.* Utility of napsin A and thyroid transcription factor 1 in differentiating metastatic pulmonary from non-pulmonary adenocarcinoma in pleural effusion. *Acta Cytol* 2011; 55: 266-270.
- Ye J, *et al.* Combination of napsin A and TTF-1 immunohistochemistry helps in differentiating primary lung adenocarcinoma from metastatic carcinoma in the lung. *Appl Immunohistochem Mol Morphol* 2011; 19: 313-317.
- Fatima N, *et al.* TTF-1 and Napsin A double stain: a useful marker for diagnosing lung adenocarcinoma on fine-needle aspiration cell blocks. *Cancer Cytopathol* 2011; 119: 127-133.
- Mukhopadhyay S, Katzenstein AL. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. *Am J Surg Pathol* 2011; 35: 15-25.
- Zhang P, *et al.* Value of napsin A and thyroid transcription factor-1 in the identification of primary lung adenocarcinoma. *Oncol Lett* 2010; 1: 899-903.
- Bishop JA, *et al.* Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. *Hum Pathol* 2010; 41: 20-25.
- Jagirdar J. Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung. *Arch Pathol Lab Med* 2008; 132: 384-396.
- Dejmek A, *et al.* Napsin A (TA02) is a useful alternative to thyroid transcription factor-1 (TTF-1) for the identification of pulmonary adenocarcinoma cells in pleural effusions. *Diagn Cytopathol* 2007; 35(8): 493-497.
- Inamura K *et al.* Pulmonary adenocarcinomas with enteric differentiation: histologic and immunohistochemical characteristics compared with metastatic colorectal cancers and usual pulmonary adenocarcinomas. *Am J Surg Pathol* 2005; 29: 660-665.
- Suzuki A, *et al.* Napsin A is useful to distinguish primary lung adenocarcinoma from adenocarcinomas of other organs. *Pathol Res Pract* 2005; 201: 579-586.
- Hirano T, *et al.* Usefulness of TA02 (napsin A) to distinguish primary lung adenocarcinoma from metastatic lung adenocarcinoma. *Lung Cancer* 2003; 41: 155-162.
- Hirano T, *et al.* Human tissue distribution of TA02, which is homologous with a new type of aspartic proteinase, napsin A. *Jpn J Cancer Res* 2000; 91: 1015-1021.

First-hand information - [www.medac-diagnostika.de](http://www.medac-diagnostika.de)


